Sanjivani Paranteral Ltd — Important, 18-02-2026: Company Update

Sanjivani Paranteral reported its financial results for the quarter and nine-month period. Consolidated revenue grew 27.1% to INR 22.1 crore, with an EBITDA margin of 18.5%. The Pune infusion facility (SPL Infusion) contributed INR 1.2 crore, marking its first revenue, and the nutraceutical venture also gained traction. The company projects base business revenue of INR 72-75 crore for this financial year, rising to INR 90 crore next financial year. SPL Infusion is targeted to add INR 60-65 crore next financial year, aiming for INR 120-130 crore peak revenue. All plants are compliant with revised Schedule M, a significant operational achievement for future growth.